Ace Therapeutics, a preclinical contract research organization specializing in analgesic drug research, has announced a comprehensive suite of end-to-end solutions for pain therapeutic development. The services include diverse validated in vivo pain models for drug testing and a complete range of preclinical research capabilities aimed at pharmaceutical and biotechnology clients worldwide.
Specializing in preclinical analgesic drug development services, Ace Therapeutics covers every stage from early target discovery and mechanism verification through pharmacological validation and safety assessment. The company's integrated in vitro and in vivo research platforms are designed to study various physiological pain mechanisms, evaluate compound efficacy, and conduct safety profiling for novel analgesic candidates.
A core strength of Ace Therapeutics lies in its extensive portfolio of standardized and customized in vivo pain models for drug testing, spanning nearly all mainstream pain classifications. These validated animal models include migraine models established via trigeminal ganglion electrical stimulation and nitroglycerin induction, as well as neuropathic pain models such as spinal nerve ligation, chronic constriction injury, and diabetic neuropathic pain models.
To complement its in vivo systems, Ace Therapeutics has developed systematic preclinical pain assessment services, including mechanical pain, thermal pain, chemical pain, cold pain, and electrical stimulation pain assessments using methods like the Von Frey Filament Test, Hot Plate Test, and Formalin Test. In vitro neuropathic pain model development services leverage dorsal root ganglion cells, iPSC-derived sensory neurons, and co-culture systems to explore pain-related cellular mechanisms.
Beyond model construction and efficacy testing, Ace Therapeutics' services extend to target-based and modality-based drug discovery, supporting research targeting G-protein coupled receptors, cytokine networks, and ion channels. The company offers professional solutions for small-molecule analgesics, biologics including antibodies, recombinant proteins, peptides, cell therapies, and gene therapy candidates. Mechanism-driven research covers peripheral inflammatory pathways, central regulatory pathways, neuronal signaling pathways, and neuro-immune interaction pathways.
The full-service pipeline also includes target validation, in vitro screening, in vivo pharmacology, pharmacokinetics analysis, safety pharmacology, preclinical formulation development, and biomarker discovery. Professional PK/PD modeling, toxicity assessment, and formulation optimization help clients reduce research risks and accelerate candidate selection. For special research needs, Ace Therapeutics can design customized pain models and testing assays according to unique drug mechanisms.
